Physician's Weekly has published a new evidence roundup on complementary treatment strategies for psoriasis, pulling together what clinicians can — and can't — reasonably tell patients who ask about add-on approaches to standard care.

The piece lands at a moment when the question is practical, not theoretical. Psoriasis affects millions of patients worldwide, most of them managed in routine dermatology practice with topical therapies, phototherapy and systemic or biologic agents graded against PASI endpoints. A substantial share of those patients also use complementary approaches — often without flagging them at the visit. The Physician's Weekly review addresses that gap directly: what does the evidence support, and how should it be framed in the consultation?

What the review covers

The roundup surveys complementary treatment strategies for psoriasis as a category. As published, it is a synthesis of existing evidence rather than a report of a new trial — there is no single new PASI figure, cohort size or regulatory decision attached to it. That distinction matters. Editorially, it's the kind of piece clinicians use to orient themselves before a shared-decision conversation, not a practice-changer with an effect size attached.

For dermatologists, the utility is in the framing. Complementary strategies sit alongside — not instead of — evidence-graded therapy. Reviews of this type typically weigh dietary modification, mind-body interventions and other non-pharmacologic add-ons against the standards used in psoriasis research, where PASI 75 and PASI 100 responses define success for systemic agents. Where the evidence class is weak or absent, the reviewer's job is to say so plainly.

Why this matters now

Psoriasis care has accelerated over the past two decades — from TNF inhibitors through IL-17 and IL-23 agents, with response ceilings that older regimens couldn't approach. But biologic access is uneven, cost sharing remains a real barrier for many patients, and interest in complementary approaches has not declined alongside biologic progress. If anything, it has grown.

That leaves a communication problem in the exam room. Patients rarely volunteer their use of complementary strategies; clinicians rarely ask systematically. An evidence roundup like this one gives physicians a current, citable baseline for those conversations — including where the honest answer is that data are limited.

What does this change for practicing dermatologists?

In practical terms: a reference point. Reviews don't prescribe, but they sharpen the advice. The takeaway for clinicians is to ask about complementary use directly, separate strategies with some evidentiary support from those without, and keep the conversation anchored to the patient's standard treatment plan rather than replacing it.

For patients, the message is simpler and worth repeating: complementary doesn't mean alternative. Anything added to psoriasis care should be disclosed, discussed and judged against the same standard as everything else in the regimen.

Whether future roundups of this kind begin attaching firmer numbers — head-to-trial comparisons, quantified adjunctive benefit — will depend on the underlying research pipeline, which for complementary strategies in psoriasis remains thin relative to the pharmacologic literature.